Human immunodeficiency virus (HIV) infection is a chronic viral disease caused by two closely related lentiviruses (HIV-1 and HIV-2) that primarily target the human immune system. After transmission, HIV establishes infection in host cells expressing CD4 and appropriate co-receptors (commonly CCR5 and/or CXCR4). Viral entry is followed by reverse transcription, whereby the viral RNA genome is converted into DNA. This viral DNA can integrate into the host genome as a provirus, enabling long-term persistence despite immune control. Over time, progressive immune dysfunction emerges, culminating in acquired immunodeficiency syndrome (AIDS), which is characterized by severe immunosuppression and susceptibility to opportunistic infections and certain malignancies.
The natural history of HIV is best understood as a continuum rather than a single event. Following acute infection, many individuals experience a transient symptomatic phase (often with fever, rash, myalgias, and lymphadenopathy). Plasma viral load is high, and transmission risk is greatest during this period. The immune system partially controls replication, leading to a clinically latent phase in which viral replication persists at lower levels. Nevertheless, the integrated provirus can remain in long-lived cellular reservoirs, including memory CD4+ T cells and other tissue compartments. Without antiretroviral therapy (ART), ongoing viral replication gradually depletes CD4+ T lymphocytes and causes chronic immune activation. This dual mechanism—direct cytopathic effects plus indirect immune-mediated injury—drives the deterioration of cell-mediated immunity.
AIDS is defined by the presence of specific opportunistic diseases or markedly reduced CD4+ T-cell counts. Typical AIDS-defining conditions include Pneumocystis jirovecii pneumonia, esophageal candidiasis, cryptococcal meningitis, certain recurrent bacterial infections, and invasive cancers such as Kaposi sarcoma and lymphomas. Importantly, the transition to AIDS is preventable when HIV is diagnosed early and ART is initiated promptly. Effective ART suppresses viral replication to undetectable levels in plasma, allowing partial immune reconstitution and a dramatic reduction in opportunistic infections.
Transmission occurs through exposure to infectious body fluids, including blood, semen, vaginal secretions, rectal fluids, and breast milk. The key routes are sexual contact, sharing injection equipment, perinatal transmission from mother to child, and needle-stick exposures in healthcare settings. Risk is influenced by viral load, presence of sexually transmitted infections, genital inflammation, condom use, and access to preventive strategies. Preventive care includes condoms, harm-reduction approaches for people who inject drugs, sterile needle programs, and testing. Biomedical prevention options include pre-exposure prophylaxis (PrEP) for HIV-negative individuals at ongoing risk and post-exposure prophylaxis (PEP) after a potential exposure when started urgently.
Diagnosis relies on laboratory testing of both antibodies and viral components. Modern algorithms often use fourth-generation antigen/antibody immunoassays, followed by confirmatory nucleic acid testing as appropriate. Because acute infection can precede seroconversion, clinicians maintain suspicion for recent exposure and employ RNA testing when indicated. Monitoring includes measuring viral load and CD4+ T-cell count to evaluate treatment efficacy, immune status, and the development of resistance.
ART is the cornerstone of HIV management. Current regimens typically combine drugs from different classes to inhibit multiple steps of the viral life cycle: entry (e.g., attachment or fusion inhibitors in select cases), reverse transcription, integration, and protease processing. Viral suppression prevents immune deterioration and reduces onward sexual transmission substantially. From a public health perspective, sustained undetectable viral load is associated with effectively eliminating transmission risk for sexual partners under appropriate conditions (“Undetectable = Untransmittable”).
Even with suppression, HIV is managed as a chronic condition. Long-term considerations include monitoring for medication-related adverse effects, comorbidities such as cardiovascular disease and metabolic disorders, mental health burden, and adherence challenges. People living with HIV may experience stigma-related stress, depression, anxiety, and social determinants that affect care continuity. Clinical guidance therefore emphasizes integrated care: antiretroviral management alongside vaccination, screening for malignancy and coinfections (including hepatitis), and support for mental wellbeing and risk reduction.
In summary, HIV infection is a persistent lentiviral disease that disrupts immune function through chronic replication, immune activation, and progressive CD4+ T-cell loss. Without treatment, this process culminates in AIDS with severe immunodeficiency and opportunistic complications. With timely diagnosis and effective ART, viral replication can be suppressed to undetectable levels, enabling immune recovery and substantially improving both individual prognosis and community transmission dynamics. Source: Stigmabase (X/Twitter) Jun 22, 2026.
STIGMABASE: S | Stigmabase about : HIV & Aids The human immunodeficiency viruses (#HIV) are two species of Lentivirus (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (#AIDS) –> [2010 to present]. #breaking
— @stigmabase May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
